London Genetics: Bridging the Gap
March 2008
London Genetics: Bridging the Gap
In this exclusive interview, Fintan Walton talks to Nick Lench, CEO of London Genetics.
London Genetics: Bridging the Gap
In this exclusive interview, Fintan Walton talks to Professor Nick Lench, CEO of London Genetics, about the company’s vision to facilitate access for biotech and pharmaceutical companies to the wealth of genetic information and expertise at a number of London’s leading academic institutes. Nick discusses the company’s overall strategy, the services that it is providing and the benefits that a single point of access brings to London’s genetics community.
Nick Lench
Nick Lench has extensive experience of knowledge and technology transfer, genetics research in academia and industry, research strategy development, intellectual property management, partnering and licensing. Before joining London Genetics, he was Professor of Medical Genetics at Cardiff University and Director of the Wales Gene Park. Between 1999 and 2003, Nick was Programme Director for Inflammation Biology and Discovery Genetics at Oxagen.
London Genetics
London Genetics Limited is a commercial company created to facilitate and manage partnerships between the healthcare industry and London centres of excellence in genetics and genomics-based medical research. It uses a multicentre approach through a consortium of leading London research institutions that includes: Imperial College London, The Institute of Cancer Research, King’s College London, the London School of Hygiene & Tropical Medicine, Queen Mary, University of London, St. George’s, University of London and University College London. The company is funded by the London Development Agency.
